Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160705 | 1.00 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4SRD5A1 | |
| SCHEMBL31731259 | 0.89 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4NPC1 | |
| SCHEMBL31731147 | 0.87 | DDB1 (0.35) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31731318 | 0.86 | DGAT1 (0.32) | DDB1CRBNDGAT1 | |
| SCHEMBL31731564 | 0.85 | DDB1 (0.34) | DDB1CRBN | |
| SCHEMBL31160670 | 0.85 | DDB1 (0.34) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31731114 | 0.84 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL31731407 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL30990711 | 0.84 | DDB1 (0.35) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL30990774 | 0.82 | DDB1 (0.33) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | DDB1 1201/4885CRBN 2290/4885DRD2 1627/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | DDB1 363/4885CRBN 2904/4885DRD2 1030/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | DDB1 270/4885CRBN 277/4885DRD2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.